Bicara Therapeutics Inc.
- Last sale
- Nov 12, 2026 · -3.80%
- Market cap
- $671.84M
- 66.39M shares
- Filings
- 266
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−80.3% FY25 yoy
- $671.84M
- —
- —
- 1.6×
- -15.94%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2024 | 2024-12-31 | $63,600,000 | reported | |
| FY 2023 | 2023-12-31 | $30,600,000 | reported |
Pharmaceutical preparations
Bicara Therapeutics Inc. is the 167th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
NVCTNuvectis Pharma, Inc.———$695.5MAPMDApnimed, Inc.———$694.6MKURAKura Oncology, Inc.$67.5M25.2%412.9%$682.7MDSGNDesign Therapeutics, Inc.$0.0——$678.5MIMMXImmix Biopharma, Inc.———$677.2MAVBPArriVent BioPharma, Inc.———$675.8M
BCAXBicara Therapeutics Inc. (this company)———$671.8M
ZVRAZevra Therapeutics, Inc.$106.5M350.9%78.2%$663.8MOLMAOlema Oncology, Inc.———$658.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR